Prosecution Insights
Last updated: April 19, 2026

Examiner: VISONE, THOMAS J

Tech Center 4100 • Art Units: 1651 1671 1672 1699 4112

This examiner grants 54% of resolved cases

Performance Statistics

54.1%
Allow Rate
-5.9% vs TC avg
481
Total Applications
+42.6%
Interview Lift
1131
Avg Prosecution Days
Based on 473 resolved cases, 2023–2026

Rejection Statute Breakdown

7.4%
§101 Eligibility
8.4%
§102 Novelty
39.6%
§103 Obviousness
26.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17230821 Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers Final Rejection Lantern Pharma Inc.
18247863 ENGINEERED GALACTOSE OXIDASE VARIANT ENZYMES Non-Final OA Codexis, Inc.
18192674 METHOD AND SYSTEM FOR DELIVERING NUCLEIC ACID Non-Final OA Hangzhou Songyin Biomedical Science and Technology Co., Ltd.
18005537 PLURIPOTENT STEM CELLS EFFECTIVE FOR TREATMENT OF MOTOR NEURON DISEASE (MND) Final Rejection LIFE SCIENCE INSTITUTE, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month